Sands Capital Ventures — 2017 Investments

1 investments dated 2017 · listed companies and verified rows first · show all

Avitideavitide.comJun 2017acquired by Repligen

Repligen provides bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows.

BiotechHardwareMedical DevicesLebanon, US

Tillman Gerngross(Director)Errik Anderson(Director)inWarren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)Kevin Isett(Executive Officer, Director)

Co-investorsOrbiMed SV Health Investors Borealis Ventures Mithril Capital Management Neomed Management Polaris Partners +1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.